16/11/2023 - Institutional news
The Universidad Francisco de Victoria (UFV), in association with the science and technology company MERCK, presents awards to researchers who have made significant clinical and scientific contributions in the field of cancer immunology research.
A study involving the Hospital del Mar Research Institute, the Vall d'Hebron Institut d'Oncologia, IDIBELL, and the Institut Català d'Oncologia suggests that combining chemotherapy with drugs that can inhibit two cell signaling pathways involved in tumor progression may aid in treatment. The research has analyzed the interaction of the protein IKKα with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing treatment toxicity. The study opens the door to new approaches for tumors with the presence of this protein. It is published in the EMBO Journal.
Més informació "A possible new combination of treatments to combat cancer"
11/10/2023 - Institutional news
The prizes were awarded at the SEOM congress held in Barcelona at the end of September. The doctoral thesis of Dr. Pedro Rocha, assistant doctor at the Oncology Department of the Hospital del Mar and researcher at the Hospital del Mar Research Institute, has received one of the five grants awarded by the Spanish Society of Medical Oncology (SEOM) to doctoral theses by young researchers. The award ceremony took place on 22 September during the congress of the organisation.
28/06/2023 - General information
The Mutua Madrileña Foundation has awarded its XX Health Research Grants, worth 2.3 million euros, to 26 clinical studies that will be carried out in hospitals throughout Spain. Six of these research projects will be carried out in Barcelona in the areas of cancer immunotherapy, rare childhood diseases, infant and juvenile mental health and transplantation, and together receive funding of more than 680,000 euros. From the Hospital del Mar Research Institute, Doctor Joaquín Arribas, will carry out a study in the field of immunotherapy in cancer. Specifically, it will perform a prospective analysis of biopsies obtained in a phase 1 clinical trial of dose increase using CAR-t Her 2 biospecific cells in patients with advanced solid tumors positive for P95HER2.
21/06/2023 - Press release
The Molecular Mechanisms of Cancer and Stem Cell Research Group of the Hospital del Mar Research Institute is the only center in Spain to participate in an international study that validates the deficiency of a protein, IκBα, as a marker of poor prognosis in this type of tumor The work, published in Cell Reports Medicine, has analyzed data from more than 2,000 patients. In addition, the researchers have identified one of the pathways on which this protein acts, which makes it a possible therapeutic target The Hospital del Mar Research Institute group is already working on a model to search for possible treatments that modulate the function of this marker. It should be considered that at present there are very few therapeutic alternatives for glioma, which has a very high mortality rate
30/03/2023 - Press release
Adding a peptide, a molecule made of several amino acids, to oxaliplatin, a chemotherapy drug used to treat colorectal cancer, avoids the side effects this treatment can have on normal cells, including potential chemotherapy resistance. This is confirmed by an article published in the Journal of Medicinal Chemistry, led by the Hospital del Mar Medical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona). This work is the second part of a recent study that explored how platinum accumulation in normal cells promotes platinum resistance in colorectal cancer cells. This new approach prevents healthy cells surrounding the tumour from accumulating platinum. This avoids the activation of certain genes linked to poor treatment response and tumour progression.
21/02/2023 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some cases of colorectal cancer accumulates in non-cancerous/healthy cells from the tumor environment. This accumulation causes healthy cells to produce a protein that further activates them, triggering tumor resistance to treatment and assisting in tumor regeneration. The researchers discovered a marker that can identify these tumors unresponsive to chemotherapy. The study, published in the journal Nature Communications, paves the way for new strategies enhancing the effects of chemotherapy on cancer cells while avoiding adverse side effects on non-cancerous cells.
13/01/23 - Events
The meeting, a success in terms of participation with more than 120 registered participants, has served to analyze the activity of the program and the strategic lines of growth. The Cancer Research Program of the Hospital del Mar Medical Research Institute held its annual meeting this morning, during which the main lines of the program were analyzed and the main challenges for the future were discussed. The initiative has been a success, with more than 120 people registered in the Josep Marull Room.
11/01/2023 - Press release
A study led by researchers from the Stem Cell and Cancer Research Group at the Hospital del Mar Medical Research Institute has revealed the key role a protein plays in identifying patients with T-cell acute lymphoblastic leukaemia who will not respond to standard treatment. The study, published in the journal EMBO Molecular Medicine, shows that combining chemotherapy with an inhibitor for this protein helps to eliminate treatment resistance in an animal model. This is a rare disease, which is diagnosed in around a hundred people each year in Spain, mainly paediatric patients.
21/12/2023 - Events
Research into immunotherapy for cancer at the Hospital del Mar Medical Research Institute has received a new boost thanks to a donation of 43,250 euros from the Amics de l’Hospital del Mar Foundation. The president of the Amics de l’Hospital del Mar Foundation, Xavier Trias, presented the cheque to the young researchers Marta Bort, Laura Ibáñez and Iván Pérez, on behalf of the research team looking into the Role of Interferon-Gamma in T cell-mediated elimination of breast cancer tumour cells, a project selected through the internal call for proposals "immunotherapy seed". This initiative is aimed at studying, through a proof of concept, some of the molecular mechanisms used by tumour cells to resist immunotherapy, with the goal of improving breast cancer treatments.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact